Last reviewed · How we verify
levo-folinic acid
levo-folinic acid is a Antidote Small molecule drug developed by National Cancer Institute, Naples. It is currently in Phase 3 development for Counteracting the toxic effects of methotrexate. Also known as: Lederfolin.
Levo-folinic acid is a form of folinic acid used to help counteract the toxic effects of methotrexate.
Levo-folinic acid is a form of folinic acid used to help counteract the toxic effects of methotrexate. Used for Counteracting the toxic effects of methotrexate.
At a glance
| Generic name | levo-folinic acid |
|---|---|
| Also known as | Lederfolin |
| Sponsor | National Cancer Institute, Naples |
| Drug class | Antidote |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by replenishing the body's stores of folate, which is necessary for the production of DNA and RNA. This helps to mitigate the damage caused by methotrexate, a chemotherapy agent that interferes with DNA synthesis.
Approved indications
- Counteracting the toxic effects of methotrexate
Common side effects
- Nausea
- Vomiting
Key clinical trials
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (PHASE3)
- A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (PHASE1, PHASE2)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU (PHASE2)
- Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC (PHASE2)
- Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (PHASE2)
- Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer (PHASE1, PHASE2)
- A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- levo-folinic acid CI brief — competitive landscape report
- levo-folinic acid updates RSS · CI watch RSS
- National Cancer Institute, Naples portfolio CI
Frequently asked questions about levo-folinic acid
What is levo-folinic acid?
How does levo-folinic acid work?
What is levo-folinic acid used for?
Who makes levo-folinic acid?
Is levo-folinic acid also known as anything else?
What drug class is levo-folinic acid in?
What development phase is levo-folinic acid in?
What are the side effects of levo-folinic acid?
Related
- Drug class: All Antidote drugs
- Manufacturer: National Cancer Institute, Naples — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Counteracting the toxic effects of methotrexate
- Also known as: Lederfolin
- Compare: levo-folinic acid vs similar drugs
- Pricing: levo-folinic acid cost, discount & access